Modular Nuclear Power, why it matters and why now! A 10 minute brief!

---

Modular Nuclear Investments — 10-Minute Investor Brief

Strategic Context

Modular nuclear power — including Small Modular Reactors (SMRs), advanced modular reactors, and micro-reactors — is emerging as a long-cycle industrial investment theme at the intersection of:

• grid reliability and baseload electrification,

• AI datacenter power requirements,

• industrial decarbonization & heat supply,

• reshoring of strategic infrastructure and energy security.

Unlike prior nuclear development cycles, current interest is driven less by ideology and more by:

• constrained power supply,

• system-level reliability gaps,

• the limits of intermittent generation in heavy industry,

• sovereign desire for secure domestic energy.

However —

Modular nuclear is not yet a mass-deployment investment story.

The investable opportunity today is primarily in:

1. fuel and fuel-services economics,

2. standardized manufacturing and component supply, and

3. engineering & deployment execution.

Pure-play SMR developers remain high-risk, binary-outcome ventures until first-of-a-kind (FOAK) reactors are financed, built, and proven repeatable.

Smart investors focus on execution signals, manufacturability, and capital discipline — not press releases or political enthusiasm.

---

What Modular Nuclear is Trying to Solve

Traditional gigawatt-scale reactors have historically faced:

• bespoke engineering,

• decade-long timelines,

• cost overruns,

• financing fragility.

Modular nuclear seeks to industrialize nuclear delivery by shifting value creation from field construction to factory manufacturing:

Traditional Megaproject	Modular Nuclear Objective
One-off custom builds	Repeatable, standardized units
On-site fabrication	Factory-built modules
Long unpredictable timelines	Shorter & controlled schedules
Cost escalation risk	Cost reductions via replication

The investment thesis becomes viable only if:

1. modules can be produced like industrial equipment, and

2. developers can demonstrate FOAK delivery without destroying capital.

Until those conditions mature, investors should expect measured, not explosive adoption.

---

Investor Evaluation Framework

To separate credible progress from narrative momentum, use three discipline filters.

---

Filter 1 — Execution Over Storytelling

Promising signals include:

• credible regulatory milestones,

• funded FOAK projects,

• sovereign, utility, or industrial customers,

• EPC and supply-chain integration,

• structured risk-sharing finance.

Weak signals include:

• roadmaps without capital backing,

• frequent timeline “resets,”

• dependency on fuel chains that don’t yet exist,

• value propositions that move faster than engineering reality.

Execution must be visible in:

• contracts,

• facilities,

• construction milestones,

—not conference stages.

---

Filter 2 — Standardization & Manufacturability

The core question:

Will these reactors become products, or remain projects?

Investors should favor programs showing:

• serial production intent,

• module yard or fabrication capability,

• standardized component qualification,

• concrete plans for replication, not prototypes.

Economic returns improve only when:

unit #5 is cheaper than unit #1

Manufacturing learning curves — not technological novelty — drive scalability.

---

Filter 3 — Capital Discipline

Nuclear history is full of capital destroyed by premature scale-up.

Sustainable programs:

• raise capital in stages,

• match hiring and scope to milestones,

• prioritize grants & strategic capital,

• avoid speculative business pivots.

Red flags:

• dilution cycles with weak execution,

• rapid headcount expansion ahead of financing,

• reliance on hype-driven narratives.

In modular nuclear:

The best companies move slow — on purpose.

---

Where Investors Are Most Likely to See Returns First

Returns are not evenly distributed across the value chain.

The most investable segments — today — are:

Priority	Segment	Why It Matters
1	Fuel cycle & uranium services	Required regardless of reactor design outcomes
2	Manufacturing & large nuclear components	Benefit from multiple programs in parallel
3	Engineering / EPC deployment	Paid early in planning & site development
4	SMR platform developers	High-risk upside only after FOAK success

The ecosystem earns revenue before SMRs scale.

Developers earn revenue only if SMRs scale.

---

Representative Public Companies by Risk Tier

(Examples — not recommendations.)

---

Lower Technology & Execution Risk — Core Exposure

Cameco (CCJ / CCO)
Uranium supply, conversion, and fuel services. Revenue visibility is driven by long-term contracting cycles and enrichment margins — not SMR timing.

BWX Technologies (BWXT)

Manufactures nuclear components and systems used across defense, commercial nuclear, and emerging SMR programs. Benefits from hardware and manufacturing standardization, not reactor design risk.

---

Moderate Risk — Industrial SMR Upside

Rolls-Royce (RR. / RYCEY)
Government-aligned UK SMR initiative with defined program structure, while core aerospace & defense segments provide cash-flow ballast.

Fluor (FLR)
Engineering and EPC execution revenue tied to early-works, planning, and program delivery across nuclear and industrial infrastructure.

---

High Risk — Venture-Style Optionality

NuScale (SMR)
Pure-play SMR developer. Upside depends on:

• FOAK financing,

• EPC execution,

• credible cost outcomes,

• manufacturing repeatability.

This is speculative by nature and should remain a small satellite position until replication evidence emerges.

---

What the Deployment Timeline Realistically Looks Like

Near-Term (0–5 Years)

Revenue concentrated in:

• fuel services,

• manufacturing orders,

• early EPC program work,

• life-extension and refurbishment of existing reactors.

Mid-Term (5–10 Years)

First modular deployments likely to appear in:

• remote / industrial power,

• military and micro-grid environments,

• early coal-replacement pilots,

• selective export demonstration projects.

Deployment will be measured and risk-managed.

Long-Term (>10 Years)

Strategic optionality:

• fleet replication,

• process-heat and hydrogen integration,

• large-scale baseload replacement,

• possible AI-adjacent energy hubs.

Treat these as potential upside, not base-case assumptions.

---

Major Catalyst Themes (2026–2030)

Confidence in the sector improves when:

• utilities sign long-term fuel contracts,

• HALEU & enriched fuel supply chains mature,

• standardized SMR regulatory pathways advance,

• manufacturing or module yard capacity is built,

• sovereign or export-financing frameworks materialize,

• EPC programs shift toward multi-site contract structures.

The most meaningful catalysts are those that shift progress:

from paper → to capital → to hardware → to replication.

Announcements without capital or construction do not materially change risk.

---

Portfolio Construction Philosophy

A disciplined modular-nuclear allocation emphasizes:

1. Fuel & manufacturing as the foundation

2. EPC & industrial partners as deployment leverage

3. Developers as controlled speculative exposure

Directional example mindsets:

Conservative approach

• Overweight Cameco + BWXT

• Moderate Rolls-Royce / Fluor

• Small NuScale satellite position

Aggressive approach

• Increase Rolls-Royce exposure

• Retain core anchors

• Allow slightly higher but still constrained developer allocation

In all cases:

SMR developers should not become core holdings until replication is visible.

---

Key Risks Investors Should Expect

This sector carries real structural risk, including:

• FOAK cost inflation and schedule slippage,

• financing delays & potential dilution,

• regulatory iteration cycles,

• supplier qualification risk,

• customer withdrawal or scope revision.

The primary investor danger is capital being deployed:

• too early,

• too concentrated,

• ahead of execution proof.

Patience, diversification across the ecosystem, and allocation discipline are essential.

---

Bottom-Line Investor Conclusions

Modular nuclear is:

• an industrial manufacturing transformation story,

• a long-cycle infrastructure buildout,

• and a capital-discipline environment — not a speculative technology sprint.

The most credible investment strategy is:

Ecosystem first
Manufacturing & EPC second
Developers only as controlled optionality

Invest where:

• cash flows already exist,

• replication improves economics,

• and execution progress can be independently verified.

Narratives will come and go.

Execution will determine who wins.

ED NOTE:

We own stock in Cameco

I asked ChatGPT, What a merger between Twist Biosciences and Ginkgo Bioworks might do for the growth of Synthetic Biology!

 

A merger between Twist Bioscience and Ginkgo Bioworks would create significant synergies due to their complementary strengths in synthetic biology and biotechnology. Here’s a detailed breakdown of the potential synergies each company would bring:

Twist Bioscience:

1. DNA Synthesis Technology:

   • Strength: Twist Bioscience is a leader in DNA synthesis technology, known for its high-throughput DNA synthesis platform.
   • Synergy: Ginkgo Bioworks could leverage Twist's efficient and scalable DNA synthesis capabilities to enhance its organism engineering processes, reducing time and costs associated with DNA synthesis.

2. Innovation in Synthetic Biology:

   • Strength: Twist has developed novel technologies for gene synthesis, gene assembly, and sequencing.
   • Synergy: Combining these innovations with Ginkgo's expertise in organism design could accelerate the development of new synthetic biology applications and products.

3. Broad Market Applications:

   • Strength: Twist serves various markets, including healthcare, industrial chemicals, agriculture, and data storage.
   • Synergy: This market diversity could complement Ginkgo’s applications, opening new avenues for revenue growth and diversification.

4. Robust Intellectual Property Portfolio:

   • Strength: Twist holds numerous patents in the field of DNA synthesis and synthetic biology.
   • Synergy: The merger would enhance the combined entity’s IP portfolio, strengthening its competitive position and protecting its technological innovations.

Ginkgo Bioworks:

1. Organism Engineering Expertise:

   • Strength: Ginkgo Bioworks is renowned for its organism engineering capabilities, designing custom microbes for various applications.
   • Synergy: Twist’s DNA synthesis could significantly improve the efficiency and success rate of Ginkgo's organism engineering projects.

2. Automated Foundries:

   • Strength: Ginkgo operates automated foundries that scale the process of designing and testing organisms.
   • Synergy: Integrating Twist’s DNA synthesis into these foundries could streamline workflows and accelerate development cycles, leading to faster time-to-market for new products.

3. Extensive Partner Network:

   • Strength: Ginkgo has established partnerships with numerous companies across various industries.
   • Synergy: These partnerships could provide new business opportunities for Twist’s technologies and products, leveraging Ginkgo’s established network for market expansion.

4. Data and Machine Learning Capabilities:

   • Strength: Ginkgo utilizes advanced data analytics and machine learning to optimize organism design and development.
   • Synergy: Combining Twist’s high-throughput DNA synthesis data with Ginkgo’s data analytics capabilities could enhance predictive modeling and improve the accuracy of synthetic biology projects.

Combined Synergies:

1. Enhanced R&D Capabilities:

   • The merger would create a powerhouse in synthetic biology, combining Twist’s cutting-edge DNA synthesis with Ginkgo’s organism engineering, leading to unprecedented R&D capabilities and innovation potential.

2. Cost Efficiency and Scalability:

   • The integration of Twist’s scalable DNA synthesis with Ginkgo’s automated foundries could lead to significant cost savings and improved scalability for synthetic biology projects.

3. Expanded Market Reach:

   • The combined entity could leverage Twist’s diverse market presence and Ginkgo’s extensive partnerships to penetrate new markets and applications, driving revenue growth and market share.

4. Accelerated Time-to-Market:

   • Synergies in technology and process integration would enable faster development cycles, allowing the combined company to bring new products and solutions to market more rapidly.

5. Stronger Competitive Position:

   • The merger would create a more robust and competitive entity in the synthetic biology space, with a comprehensive technology portfolio and a strong IP position.

Overall, a merger between Twist Bioscience and Ginkgo Bioworks would likely result in a powerful synergy that enhances technological capabilities, operational efficiencies, market reach, and competitive strength in the rapidly evolving field of synthetic biology.

Here are two small cap future tech companies we like in the synthetic biology space going forward!

 

From ChatGPT

Twist Biosciences and Ginkgo Bioworks: Business Models and Applications

Twist Biosciences

Business Model: Twist Biosciences specializes in synthetic DNA production using a silicon-based DNA synthesis platform. Their business model focuses on:

1. Custom DNA Synthesis: Providing custom DNA sequences for various applications in biotechnology and research.
2. Next-Generation Sequencing (NGS) Tools: Offering tools and services that aid in sequencing and analyzing genetic material.
3. Synthetic Biology Applications: Supplying synthetic genes and gene fragments for developing new biological products.
4. Biopharmaceuticals and Diagnostics: Developing and providing DNA-based tools for the development of new drugs and diagnostic tests.

Key Applications:

• Research and Development: Enabling academic and commercial research with custom DNA synthesis.
• Biopharma: Assisting in the development of therapeutics and vaccines.
• Agriculture: Enhancing crop genetics for better yield and resistance.
• Industrial Biotechnology: Producing enzymes and other industrial proteins.
• Diagnostics: Creating high-precision diagnostic tests.

Ginkgo Bioworks

Business Model: Ginkgo Bioworks operates as a synthetic biology platform company, focusing on designing custom organisms for various industries. Their business model includes:

1. Organism Engineering: Developing customized microorganisms for specific applications in multiple sectors.
2. Biosecurity: Providing services to detect, monitor, and respond to biological threats.
3. Partnerships and Collaboration: Collaborating with companies across various industries to apply synthetic biology solutions.
4. Cell Programming: Offering cell programming services to design and optimize biological production systems.

Key Applications:

• Pharmaceuticals: Developing microorganisms that can produce pharmaceutical ingredients.
• Agriculture: Engineering microbes to improve soil health and crop productivity.
• Industrial Manufacturing: Creating bio-based manufacturing processes to produce chemicals, materials, and biofuels.
• Food and Beverages: Enhancing the production of food ingredients and improving food processing techniques.
• Environmental Solutions: Developing organisms that can help in bioremediation and waste treatment.

Prospects for Growth

Twist Biosciences

Growth Drivers:

1. Increasing Demand for DNA Synthesis: The rise in genetic research and biotechnology innovations fuels the demand for custom DNA synthesis.
2. Advancements in Synthetic Biology: As synthetic biology grows, the need for high-quality, customizable DNA sequences will likely increase.
3. Expansion into New Markets: Twist Biosciences can expand its product offerings into new applications such as personalized medicine and advanced diagnostics.
4. Strategic Partnerships: Forming partnerships with pharmaceutical and biotech companies can drive growth through collaborative R&D projects.

Challenges:

• Competition: Facing competition from other DNA synthesis companies and advancements in alternative synthesis technologies.
• Regulatory Hurdles: Navigating complex regulatory environments, especially in the biopharmaceutical sector.
• Scalability: Scaling production while maintaining quality and reducing costs.

Ginkgo Bioworks

Growth Drivers:

1. Broad Application Spectrum: The versatility of synthetic biology allows Ginkgo to tap into diverse industries such as pharmaceuticals, agriculture, and industrial manufacturing.
2. Biosecurity Initiatives: Growing focus on biosecurity and pandemic preparedness presents new opportunities for Ginkgo's expertise.
3. Collaborative Model: Expanding collaborations with companies across different sectors can lead to new revenue streams and innovations.
4. Sustainability Trends: Increasing demand for sustainable and environmentally friendly solutions boosts the relevance of Ginkgo's bioengineering capabilities.

Challenges:

• Regulatory and Ethical Issues: Navigating the regulatory landscape and addressing ethical concerns related to genetic engineering.
• Market Adoption: Convincing traditional industries to adopt synthetic biology solutions.
• Technological Challenges: Overcoming technical hurdles in organism engineering and scaling up production.

Comparative Summary

• Focus: Twist Biosciences is heavily focused on DNA synthesis and applications primarily in research, diagnostics, and biopharma, whereas Ginkgo Bioworks has a broader synthetic biology platform approach, targeting various industries.
• Business Model: Twist follows a product-centric model providing custom DNA and NGS tools, while Ginkgo operates a service-oriented model through organism engineering and cell programming.
• Growth Prospects: Both companies have strong growth potential driven by advancements in biotechnology, but Twist might experience more linear growth driven by DNA synthesis demand, whereas Ginkgo's diverse application potential could lead to exponential growth across various sectors.
• Challenges: Both face regulatory and scalability challenges, but Ginkgo also has to address market adoption hurdles across different industries.

Overall, both Twist Biosciences and Ginkgo Bioworks are well-positioned for future growth, leveraging advancements in synthetic biology and biotechnology. Their success will depend on their ability to innovate, scale, and navigate regulatory landscapes while forming strategic partnerships to expand their market reach.

I asked ChatGPT, What a merger between Twist Biosciences and Ginkgo Bioworks might do for the growth of Synthetic Biology!

As Healthcare and Biotech companies utilize cutting edge Ai technology, more and more diseases will be conquered.

 Let’s take a look at the treatments offered by three, up and coming, BioTech companies with cutting edge therapies, that are currently on our watch list!

 (No positions at this writing):

1. Syndax Pharmaceuticals:

   • Axatilimab: An anti-CSF-1R monoclonal antibody. It’s being developed for chronic graft-versus-host disease (cGVHD) and other immune-mediated diseases where CSF-1R-dependent monocytes and macrophages contribute to organ fibrosis.
   • Revumenib: Received FDA Breakthrough Therapy Designation for treating adult and pediatric patients with relapsed or refractory KMT2A-rearranged MLLr acute leukemia.

2. Autolus Therapeutics:

   • Autolus is focused on developing next-generation programmed T-cell therapies for cancer. They have several clinical-stage candidates, including AUTO1, AUTO3, and AUTO4, which target different types of leukemia and lymphoma. These therapies are still in clinical trials.

3. Xencor Inc.:

   • Xencor is known for its XmAb antibody engineering platform. While they don’t have direct treatments, they collaborate with other companies to develop novel therapies using their technology
   • -----------------------------------------------------------------------------------------------------------------------------------------

In summary, Syndax Pharmaceuticals has made notable progress, while Autolus Therapeutics is primarily in clinical trials, and Xencor focuses on antibody engineering. 

As of today, Autolus Therapeutics and Syndax Pharmaceuticals have been in the spotlight, with analysts weighing in on their potential. Let’s take a closer look:

1. Autolus Therapeutics (AUTL):

   • Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics, setting a price target of $9.00. The company’s shares closed last Friday at $4.501.
   • Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.
   •  They recently announced the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel), which targets patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (B-ALL)2.

2. Syndax Pharmaceuticals (SNDX):

   • Syndax is advancing the next generation of targeted treatments for cancer. They focus on acute leukemias and chronic graft-versus-host disease.
   • Recently, Syndax reported its financial results for the first quarter of 2024 and provided a business update
   • 
     
   • There’s no specific information regarding any of the three being takeover targets at the moment. 
   • Keep an eye on news and analyst reports for any updates on these companies and remember, that, the big dogs of BioTech are always on the lookout for smaller companies with great new technology!

Agenus Inc. (formerly known as Agenus Therapeutics) is not claiming to be close to a cure for any form of cancer, but they are making significant strides in developing innovative cancer therapies.

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

Can two small caps become the kings of synthetic biology? Only time will tell!

 Both Twist Biosciences and Ginkgo Bioworks are prominent players 

in the field of  Synthetic biology, but they have different focuses and strengths.

Let’s take a closer look at each company: Twist Biosciences: Core Focus: Twist Biosciences specializes in high-quality synthetic DNA production using its Silicon Platform. They offer custom DNA synthesis services to researchers, biotech companies, and other organizations. Technology: Their Silicon Based DNA synthesis platform allows for efficient and precise DNA manufacturing. Applications: Twist’s DNA products are used in various applications, including Gene Editing, vaccine development, Drug discovery, and more. Collaboration with Ginkgo: Twist has a collaboration with Ginkgo Bioworks, which includes a four-year supply agreement. Ginkgo purchases products from Twist, allowing them to test proteins and develop diverse solutions across multiple industries. Recent Deal: In 2022, Twist agreed to supply at least 100 million base pairs of synthetic DNA to Ginkgo over a one-year period for engineering prototype organisms. Ginkgo Bioworks: Core Focus: Ginkgo is a horizontal platform for cell programming. They aim to make programming cells as easy as programming computers. Technology: Ginkgo’s platform enables biotechnology applications across various markets, including food, agriculture, industrial chemicals, and pharmaceuticals. Applications: Ginkgo focuses on organism design and engineering, optimization, and other synthetic biology services. Collaboration with Twist: Ginkgo collaborates with Twist to secure high volumes of DNA. They have ordered approximately one billion base pairs of synthetic DNA from Twist over the past four years for various programs. Expansion Plans: Ginkgo’s collaboration with Twist aims to fuel their expansion plans in the synthetic biology field. In summary, both companies contribute significantly to the synthetic biology ecosystem, but their expertise lies in different areas.

Twist excels in DNA synthesis, while Ginkgo focuses on cell programming and organism engineering.

The collaboration between these two organizations demonstrates their commitment to advancing the field of synthetic biology.

Foot notes:

Most recently Googles "Deep Mind" Ai has been used in combination with Synbio, cell programming and gene editing, to further the advancement in cooperation with a number of companies.

With the deep, data set of Alphabet, combined with Deep Mind's cutting edge Ai, and the massive data bank that is the human DNA, medicine and medical disciplines will benefit immensely from what is coming! And, so will human kind!